Search through
Rabeprazole Sodium and Domperidone Sustained-Release Pellets (CAS 117976-90-6 and 57808-66-9) are increasingly sought after in the high purity fine chemicals sector as American CDMOs prioritize fixed-dose combination therapies to address the growing prevalence of gastroesophageal reflux disease (GERD) and motility disorders. The domestic market for these enteric-coated and sustained-release delivery systems has seen a strategic pivot toward custom synthesis services to ensure precise release kinetics that meet stringent FDA bioequivalence standards, especially as bulk chemical supplier networks diversify to mitigate global supply chain risks. Advanced proton pump inhibitor and dopamine antagonist formulations are currently driving innovation in the United States pharmaceutical landscape, where rigorous adherence to cGMP manufacturing and the availability of comprehensive analytical validation through HPLC and NMR are essential for ensuring domestic regulatory compliance. We are an established Rabeprazole Sodium 20Mg + Domperidone 30Mg SR Pellets api supplier with Rabeprazole Sodium 20Mg + Domperidone 30Mg SR Pellets >= 99% purity for semi-finished formulators in the american region , providing comprehensive analytical (HPLC/NMR/MS) and supporting Rabeprazole Sodium 20Mg + Domperidone 30Mg SR Pellets COA/TDS/SDS region-specific regulatory support. reliable lead times, United states nationwide supply chain capabilities
Rabeprazole Sodium and Domperidone Sustained-Release Pellets (CAS 117976-90-6 and 57808-66-9) are increasingly sought after in the high purity fine chemicals sector as American CDMOs prioritize fixed-dose combination therapies to address the growing prevalence of gastroesophageal reflux disease (GERD) and motility disorders. The domestic market for these enteric-coated and sustained-release delivery systems has seen a strategic pivot toward custom synthesis services to ensure precise release kinetics that meet stringent FDA bioequivalence standards, especially as bulk chemical supplier networks diversify to mitigate global supply chain risks. Advanced proton pump inhibitor and dopamine antag...
.7767eb0f.png)
Chemical Properties & Specifications
P261, P264+P265, P272, P280, P302+P352, P305+P351+P338, P321, P333+P317, P337+P317, P362+P364, and P501
Skin Sens. 1 (96.4%)
Eye Irrit. 2A (100%)
A combination therapeutic agent containing a proton pump inhibitor and a dopamine antagonist used for the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and acid-related indigestion
A clinically formulated fixed-dose combination of rabeprazole sodium and domperidone sustained-release pellets designed to provide rapid acid reduction and improved gastric motility for the management of hypersecretory conditions and nausea.
Rabeprazole Sodium 20Mg + Domperidone 30Mg SR Pellets is a combination medication used to treat gastrointestinal disorders such as gastroesophageal reflux disease (GERD), acid reflux, heartburn, and peptic ulcers by reducing stomach acid and improving gut motility
This combination is primarily used in the pharmaceutical industry for the production of gastrointestinal medicines and antacid formulations
It is commonly formulated into sustained-release (SR) or delayed-release capsules and tablets, often featuring enteric-coated pellets to ensure optimal absorption and long-lasting relief
Standard documentation provided includes COA, TDS, impurity reports, and regulatory compliance documents to ensure high purity and pharmaceutical grade quality
Scimplify has capabilities for global distribution and custom synthesis through an integrated network of manufacturers and logistics partners with reliable lead time
The product is export ready with a standard MOQ starting from 100 kgs, with lead times for international customers depending on the shipping destination and specific grade.